|Day Low/High||1.05 / 1.09|
|52 Wk Low/High||1.03 / 4.12|
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.
Buyers expect a dovish Fed and are still trying to put money to work.
Stocks were falling slightly in premarket trading Tuesday as oil continued its six-day descent.
The problem for the bears is that there are still plenty of folks trying to extract some gains from the upside.
Earnings reports produce mixed market reaction as stocks slip after Wednesday's rally.